Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling.

Budanov AV, Karin M.

Cell. 2008 Aug 8;134(3):451-60. doi: 10.1016/j.cell.2008.06.028. Erratum in: Cell. 2009 Jan 23;136(2):378.

2.
3.

The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.

Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS.

Cell Cycle. 2009 Dec 15;8(24):4168-75.

4.

The coordinate regulation of the p53 and mTOR pathways in cells.

Feng Z, Zhang H, Levine AJ, Jin S.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9. Epub 2005 May 31.

5.

The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases.

Zajkowicz A, Rusin M.

Mech Ageing Dev. 2011 Nov-Dec;132(11-12):543-51. doi: 10.1016/j.mad.2011.09.002. Epub 2011 Sep 21.

PMID:
21945951
6.

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.

Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL.

Cell. 2006 Sep 8;126(5):955-68.

7.

Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.

Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF 3rd, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR Jr, Linehan WM, Schmidt LS, Zbar B.

Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15552-7. Epub 2006 Oct 6.

8.

Mind the GAP: Wnt steps onto the mTORC1 train.

Choo AY, Roux PP, Blenis J.

Cell. 2006 Sep 8;126(5):834-6.

9.

The LKB1 tumor suppressor negatively regulates mTOR signaling.

Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC.

Cancer Cell. 2004 Jul;6(1):91-9.

10.

Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.

Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M, Stahel RA.

BMC Cancer. 2012 Dec 4;12:571. doi: 10.1186/1471-2407-12-571.

11.

LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.

Shaw RJ.

Acta Physiol (Oxf). 2009 May;196(1):65-80. doi: 10.1111/j.1748-1716.2009.01972.x. Epub 2009 Feb 19. Review.

12.

RhoE is a pro-survival p53 target gene that inhibits ROCK I-mediated apoptosis in response to genotoxic stress.

Ongusaha PP, Kim HG, Boswell SA, Ridley AJ, Der CJ, Dotto GP, Kim YB, Aaronson SA, Lee SW.

Curr Biol. 2006 Dec 19;16(24):2466-72. Erratum in: Curr Biol. 2012 Nov 20;22(22):2186-7.

13.

REDD2 is enriched in skeletal muscle and inhibits mTOR signaling in response to leucine and stretch.

Miyazaki M, Esser KA.

Am J Physiol Cell Physiol. 2009 Mar;296(3):C583-92. doi: 10.1152/ajpcell.00464.2008. Epub 2009 Jan 7.

14.

The RNA surveillance protein SMG1 activates p53 in response to DNA double-strand breaks but not exogenously oxidized mRNA.

Gewandter JS, Bambara RA, O'Reilly MA.

Cell Cycle. 2011 Aug 1;10(15):2561-7. Epub 2011 Aug 1.

15.

Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR.

Dere R, Wilson PD, Sandford RN, Walker CL.

PLoS One. 2010 Feb 16;5(2):e9239. doi: 10.1371/journal.pone.0009239.

16.
17.

IFI16 induction by glucose restriction in human fibroblasts contributes to autophagy through activation of the ATM/AMPK/p53 pathway.

Duan X, Ponomareva L, Veeranki S, Choubey D.

PLoS One. 2011 May 5;6(5):e19532. doi: 10.1371/journal.pone.0019532.

18.

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J.

Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94. Epub 2004 Sep 1.

19.

FM19G11: A new modulator of HIF that links mTOR activation with the DNA damage checkpoint pathways.

Rodríguez-Jiménez FJ, Moreno-Manzano V, Mateos-Gregorio P, Royo I, Erceg S, Murguia JR, Sánchez-Puelles JM.

Cell Cycle. 2010 Jul 15;9(14):2803-13. Epub 2010 Jul 3.

PMID:
20676050
20.

Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma.

Kong B, Cheng T, Qian C, Wu W, Steiger K, Cao J, Schlitter AM, Regel I, Raulefs S, Friess H, Erkan M, Esposito I, Kleeff J, Michalski CW.

Mol Cancer. 2015 Dec 18;14:212. doi: 10.1186/s12943-015-0483-1.

Supplemental Content

Support Center